A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response (clinicaltrials.gov) - Oct 16, 2026 - P1 | N=88 | Not yet recruiting | Sponsor: Adaxion Therapeutics
New P1 trial
|